The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.
Definite infective endocarditis according to the 2023 Duke ISCVID criteria or confirmed by the endocarditis team if the endocarditis was classified as possible
Prosthetic valve endocarditis
At least one positive blood culture due to Staphylococcus sp (S. aureus or CoNS)
After the first positive blood culture, at least one negative blood culture (after a minimum of 72 hours of incubation)
Presence of cardiovascular implanted electronic device with suspected device-related IE without removal of the device
Expected duration of follow-up <6 months at the time of randomization
Patient moribund (expected to die in next 48 hours with or without treatment)
Patients already receiving more than 72 hours of rifampin for the endocarditis treatment prior to randomization